Standard management of sickle cell disease complications

Miguel R Abboud

doi:10.1016/j.hemonc.2019.12.007

Standard management of sickle cell disease complications

Hematol Oncol Stem Cell Ther. 2020 Jun;13(2):85-90. doi: 10.1016/j.hemonc.2019.12.007. Epub 2020 Mar 12.

Author

Miguel R Abboud¹

Affiliation

¹ Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: [email protected].

PMID: 32202245
DOI: 10.1016/j.hemonc.2019.12.007

Abstract

Sickle cell disease remains a major public health concern in sub-Saharan Africa, Europe, and the United States. The survival rate of children and adolescents has increased immensely in developed countries, whereas the survival rate for adults lagged behind. The increase in the pediatric survival rate is attributable to the institution of hydroxyurea treatment as well as stroke prevention strategies. In this review, we discuss the management of the sickle disease major complications such as pain, stroke, and acute chest syndrome with the most current hydroxyurea use and transfusion therapy.

Keywords: Acute chest syndrome; Hydroxyurea and transfusion; Sickle cell disease.

Publication types

Review

MeSH terms

Adolescent
Anemia, Sickle Cell / complications*
Blood Transfusion / methods*
Child
Child, Preschool
Female
Humans
Male